Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPGM | P07738 | 6/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.33 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.32 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | GHSR | Q92847 | 1/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.31 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24348045 | 0.95 | BPGM (0.47) | BPGMGRIN2BTRPC3TRPC7HTR2C | |
| SCHEMBL24348425 | 0.94 | BPGM (0.48) | BPGMGRIN2BMAP3K5F2RL3 | |
| SCHEMBL24348462 | 0.93 | BPGM (0.45) | BPGMGRIN2BTRPC3TRPC7USP30 | |
| SCHEMBL24348391 | 0.92 | BPGM (0.44) | BPGMGRIN2BTRPC3TRPC7USP30 | |
| SCHEMBL24348468 | 0.92 | BPGM (0.44) | BPGMGRIN2BTRPC3TRPC7 | |
| SCHEMBL24349259 | 0.91 | BPGM (0.37) | BPGMGRIN2BUSP30 | |
| SCHEMBL24348430 | 0.91 | BPGM (0.36) | BPGMGRIN2BTRPC3TRPC7USP30 | |
| SCHEMBL24348019 | 0.90 | BPGM (0.50) | BPGMHTR2CADORA2AADORA2B | |
| SCHEMBL24348423 | 0.87 | BPGM (0.41) | BPGMHTR2CADORA2AADORA2B | |
| SCHEMBL24348395 | 0.86 | BPGM (0.47) | BPGMGRIN2BTRPC3TRPC7HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348454-A1 | COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| US-20230348454-A1 | COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| WO-2022056449-A1 | COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348454-A1 | COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | BPGM, PGAM1, HBG1 | BPGM 1/4885GRIN2B 3822/4885TRPC3 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.